| 291.86 -19.89 (-6.38%) | 10-30 16:02 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 365.34 | 1-year : | 426.72 |
| Resists | First : | 312.79 | Second : | 365.34 |
| Pivot price | 297.58  |
|||
| Supports | First : | 286.49 |
Second : | 270.24 |
| MAs | MA(5) : | 302.98 |
MA(20) : | 292.84 |
| MA(100) : | 308.56 |
MA(250) : | 328.95 |
|
| MACD | MACD : | 4.4 |
Signal : | 3.2 |
| %K %D | K(14,3) : | 75.4 |
D(3) : | 82.3 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 386.02 | Low : | 266.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SYK ] has closed above bottom band by 34.4%. Bollinger Bands are 2.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 299.42 - 301.14 | 301.14 - 302.69 |
| Low: | 278.39 - 280.19 | 280.19 - 281.81 |
| Close: | 289.08 - 292.04 | 292.04 - 294.72 |
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Sun, 01 Nov 2026
Stryker Corporation (SYK) Stock Forecasts - Yahoo! Finance Canada
Fri, 30 Oct 2026
Stryker Corporation (SYK) Seasonal returns chart - Yahoo Finance UK
Fri, 30 Oct 2026
Stryker Corporation Q3 2026 Earnings Call Summary - Yahoo Finance
Fri, 30 Oct 2026
What Stryker (SYK) Said on Its Q3 Earnings Call - Yahoo Finance
Fri, 30 Oct 2026
Stryker Corp (SYK) (Q3 2026) Earnings Call Highlights: Solid Organic Growth and Margin ... - Yahoo Finance
Thu, 29 Oct 2026
Stryker Corporation (SYK) Shares Drop 13% After Q3 Earnings Miss and Lowered Guidance - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 384 (M) |
| Shares Float | 348 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 83 (%) |
| Shares Short | 5,740 (K) |
| Shares Short P.Month | 7,640 (K) |
| EPS | 9.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 62.54 |
| Profit Margin | 14.4 % |
| Operating Margin | 27 % |
| Return on Assets (ttm) | 8.1 % |
| Return on Equity (ttm) | 16.5 % |
| Qtrly Rev. Growth | 9.3 % |
| Gross Profit (p.s.) | 44.19 |
| Sales Per Share | 67.36 |
| EBITDA (p.s.) | 19.24 |
| Qtrly Earnings Growth | 44 % |
| Operating Cash Flow | 5,530 (M) |
| Levered Free Cash Flow | 4,110 (M) |
| PE Ratio | 30.23 |
| PEG Ratio | 1.4 |
| Price to Book value | 4.66 |
| Price to Sales | 4.33 |
| Price to Cash Flow | 20.23 |
| Dividend | 0.87 |
| Forward Dividend | 0 |
| Dividend Yield | 0.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|